title: Thrombin inhibition during PCI in heart failure patients.
abstract: In this retrospective analysis, CHF patients undergoing PCI had a decrease in mortality, bleeding, and transfusion as well as decreased length of stay and hospital cost when bivalirudin was used when compared to heparin. This study suggests bivalirudin may be the preferred anticoagulant for patients with CHF undergoing PCI. Confirmation of these data might entail analysis of patient-level, pooled data from randomized controlled trials comparing bivalirudin to heparin in PCI patients with pre-existing CHF.
authors.affiliation: Cardiac Catheterization Laboratory, Division of Cardiology, Tufts Medical Center, Boston, Massachusetts.
authors.forename: Yusuf
authors.initials: Y
authors.lastname: Bader
authors.affiliation: Cardiac Catheterization Laboratory, Division of Cardiology, Tufts Medical Center, Boston, Massachusetts.
authors.forename: Carey
authors.initials: C
authors.lastname: Kimmelstiel
mesh_terms: D015906:Angioplasty, Balloon, Coronary; D000925:Anticoagulants / Q000627:therapeutic use; D000991:Antithrombins / Q000627:therapeutic use*; D006333:Heart Failure; D006470:Hemorrhage; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D011994:Recombinant Proteins; D012189:Retrospective Studies; D013917:Thrombin; D016896:Treatment Outcome
chemical_list: D000925:Anticoagulants; D000991:Antithrombins; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D011994:Recombinant Proteins; D006493:Heparin; D013917:Thrombin